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CLINICAL AUDIT AND REFORM OF THE UK RESEARCH ETHICS REVIEW SYSTEM 
Emma CAVE and Christopher NICHOLS* 
ABSTRACT. There is an international consensus that medical research involving 
humans should only be undertaken in accordance with ethical principles. Paradoxically 
though, there is no consensus over the kinds of activities that constitute research 
and should be subject to review. In the UK and elsewhere, research requiring 
review is distinguished from clinical audit. Unfortunately the two activities are not 
always easy to differentiate from one another. Moreover, as the volume of audit 
increases and becomes more formal in response to the demand for evidence-based 
practice in medicine, the overlap between research and audit grows more acute. 
Arguably, similar ethical standards and systems for ensuring that those standards are 
met should be applied regardless of whether or not a project is classified as research 
or audit. At a time when the research ethics review system in the UK is undergoing 
significant reform it is important that the opportunity is not missed to address the 
longstanding research-audit problem. We discuss suggestions for further reform that 
addresses this issue. 
INTRODUCTION 
Which activities should be subject to ethical review by research ethics 
committees (RECs)? The obvious and traditional answer is that if the 
activity qualifies as research then it falls within the remit of RECs.1 
Unfortunately, research is notoriously difficult to define. The purpose 
or objective of most research is new and generalizable knowledge. 
Clinical audit, on the other hand, is used to monitor the 
standard of care received by patients or outcomes of treatment. Audit 
is a cyclical activity designed to monitor service quality. Standards 
are defined, evidence is gathered about performance and the results 
are compared against standards. Actions are then taken, if necessary, 
to improve practice and the cycle begins again. But both research and 
audit may utilise similar methodologies or expose participants to risk 
of similar kinds of harm. We need to separate the problem of defining 
research from the problem of defining the limits of ethical review. 
Recent focus on quality and standards in health services means 
that interest in audit is increasing. Audits are becoming more formal, 
sophisticated and increasingly results are published in peer reviewed 
journals. Greater overlap between research and audit is problematic 
for investigators, research ethics committees, and journal editors as 
opinions differ over the requirement for ethical review. This can lead 
to delays in the commencement of audit and publication difficulties. 
In addition, the lack of both clear ethical guidelines for audit and a 
robust system of compliance puts participants at risk and potentially 
erodes public support. 
 
Whilst ethical review of research is widely accepted, the REC 
system has come in for heavy criticism from researchers who find the 
process overly burdensome and slow.2 Therefore, any expansion of 
ethical review to encompass audit must be carefully balanced so that 
it does not disproportionately impede good quality studies. In Australia, 
these issues were at the heart of reform of the ethical review 
system. We consider whether lessons learned from the Australian 
example can be applied to the evolving UK NHS national research 
ethics service. 
 
THE CHANGING NATURE OF CLINICAL AUDIT IN A POST-BRISTOL NHS 
In 1999, scandal hit the National Health Service (NHS) when doctors 
carrying out complex heart surgery on children in Bristol were found 
to have done so despite higher death rates for such surgery than their 
colleagues. One of the outcomes of the Bristol Royal Infirmary 
Inquiry,3 chaired by Sir Ian Kennedy, was to reignite interest in 
clinical audit. Not only has this contributed to an increase in the 
volume of clinical audit, but the nature of audit has also changed. 
Greater formality and rigour in the audit process together with wider 
dissemination and interest in the results of audit has meant that the 
line distinguishing it from other kinds of research has become 
increasingly blurred. 
 
Clinical quality was not a policy issue before the 1980s when 
public concern first arose over variations in practice and outcomes. 
Until that time the emphasis was firmly on professional autonomy 
and self-regulation.4 In 1985 the World Health Organisation called 
on member states to introduce quality systems,5 and in 1989 a formal 
structure was finally implemented.6 The US ‘total quality management’ 
model was favoured.7 Audit became a branch of quality 
assurance, along with other intelligence-gathering activities including 
review, evaluation, surveillance, appraisal and monitoring.8 Audit 
may be medical, clinical or organisational: 
 
Clinical audit refers to audit covering all aspects of clinical care, including that 
provided by nursing and paramedical staff. Medical audit refers to audit of activities 
initiated directly by doctors. Organisational audit refers to investigation of aspects of 
practice such as appointments systems which are regarded as primarily administrative.9 
 
Here we concentrate on clinical audit where the grey area between 
research and audit is most apparent. From 1989, the responsibility of 
the NHS to monitor quality extended to cover clinical audit. Clinical 
audit was traditionally the exclusive domain of clinicians. It was seen 
largely as an ad hoc teaching aid which formed part of the system of 
professional self-regulation. Critics pointed out the difficulties of 
achieving good clinical audit,10 and the ethical issues that some audit 
raises.11 
 
One of the effects of the Bristol Royal Infirmary (BRI) debacle 
was to renew the demand for monitoring and accountability of 
doctors.12 The Bristol Royal Infirmary Inquiry recommended that 
clinical audit should be at the core of a system of local monitoring of 
performance; that it should be fully supported by the local NHS 
Trusts which commission services for hospitals and General Practitioners’ 
practices; and should be compulsory for all healthcare professionals 
providing clinical care.13 More rigorous standards in terms 
of study design and data analysis now apply to audit and the results 
of audits are much more likely to be published than in the past, 
making the distinction between audit and research much more 
difficult to draw. 
 
PURPOSIVE DEFINITIONS OF RESEARCH AND AUDIT: NO LONGER FIT FOR PURPOSE? 
 
Audit is a species of quality improvement / quality assurance, which 
has its roots in management. In contrast, research has its roots in 
science and academia. There have been numerous attempts to provide 
simple definitions differentiating research from audit: 
 
Research is concerned with discovering the right thing to do; audit with ensuring that 
it is done right.14 
Research...helps to answer the question ‘what is best practice?’ Clinical audit answers 
the question ‘are we following best practice?’15 
Perhaps the most helpful distinction [between research and audit] is about motivation 
and the objectives of the project: audit has the objective of directly improving 
services against a standard; research may include the objective of defining best 
practice.16 
In the majority of cases research and audit can adequately be 
distinguished on the basis of their different objectives or purposes. 
However, this approach is limited as it fails to deal with activities that 
are multifunctional. Some studies exhibit features of both research 
and audit. This has left investigators and research ethics committee 
members in a sea of confusion. 
 
The United Bristol Healthcare Trust (UBHT) has recently issued 
two simple guides attempting to define first clinical audit17 and second 
the ethical issues contained therein.18 The former document seeks 
to differentiate between the two on the basis of purpose, a line followed 
in the Central Office for NHS Research Ethics Committee’s 
(COREC’s) recent guidance.19 The latter document examines 
potential ethical issues arising in audit, concentrating in particular on 
confidentiality issues. It concludes that audit does not require independent 
ethical review except in two situations: 
 
1) if the study is research and not audit. The document points out that audit never 
involves ‘experimentation on patients, placebo or new treatments, allocation of 
subjects to control groups or randomisation or any disturbance to the patient beyond 
that required for routine clinical management’.20 The guide recognises that a ‘purposive’ 
approach will not always work and the grey areas must be resolved with 
dialogue between the Research and Effectiveness Department, the Clinical Audit 
Team and the relevant NHS REC. In those cases where the project contains elements 
of both audit and research, the document recommends that ethics approval be 
obtained. 
2) if the study involves a patient survey.21 The advice, again, is to look to purpose to 
determine whether the survey is research or audit. If it is audit, then ethical approval 
will not be required though ‘there are still a number of questions you should address 
which have an ethical dimension’.22 Some such questions are listed. 
 
This guidance is as clear as an approach based on definitions of 
research and audit can be, but borderline cases are not easily 
resolved, and some audit will raise ethical issues that will not be 
subjected to independent ethical review. The UBHT advises that 
research ethics committees are consulted in cases of doubt. The Royal 
College of Physicians gives similar advice,23 but then ethics committees 
are faced with the same difficulty. 
 
Although there are differences between audit and research, there 
are also significant similarities, the most relevant being the involvement 
of patients and the use of their personal information. Ethical 
review does not exist because research is concerned with generalizable 
knowledge. Rather ethical review exists to protect research participants 
from risks of research. This level of paternalism is justified 
because of the imbalance in power and knowledge that is manifest in 
the doctor-patient relationship, which gives rise to the potential for 
undue influence. The same doctor-patient relationship and the associated 
risk of undue influence are potentially as prevalent in clinical 
audit as they are in some types of clinical research. 
 
The burdens and risks involved in research are justified on the 
basis that research contributes to the public good. Yet the public 
good of research lies not in the contribution it makes to generalisable 
knowledge per se, but in the subsequent improvement in the treatment 
and care of future patients that results from the application of 
that knowledge. Thus in terms of the relevant ethical considerations, 
the purpose of research is more appropriately expressed as the 
improvement of healthcare for future patients. Exactly the same can 
be said of the purpose of clinical audit. 
 
In summary, both the benefits and the burdens of clinical audit 
and other types of clinical research are similar in kind. Both involve 
methods that potentially expose participants to burdens and risks of 
psychosocial harm and undue influence. Both activities are ethically 
justified if the public benefit in terms of the contribution made to 
further improvements in healthcare for future patients outweighs the 
burden and risk to the participant. Ethically, clinical audit and other 
research differ only in degree, not in kind. As a result, there can be no 
clear dividing line between the two activities. UK regulations which 
attempt to drive a wedge between research and clinical audit are 
flawed. 
 
THE CONSEQUENCES OF DRAWING INAPPROPRIATE 
DISTINCTIONS BETWEEN RESEARCH AND AUDIT 
 
The difficulty distinguishing between clinical audit and research is not 
merely semantic. This uncertainty has important consequences because 
of the different ways in which audit and research are regulated. 
Whilst all research protocols must receive prior approval by a REC, 
audit is exempt from this requirement. Given that the REC system 
has been strongly criticised for being too cumbersome and bureaucratic, 24  
any opportunity to circumvent the system must be tempting. 
Additionally, the arrangements for ensuring that audit conforms to 
appropriate ethical standards are fragmented and lack clarity. Where 
audit poses risks to participants or overlaps with research there is a 
case for greater consistency in ethical standards, including the 
requirement for prior ethical review.25 Participants in clinical audit 
may be recruited to projects that would not have been approved by 
an ethics committee had they been labelled as research. There are 
problems too for the investigator. He may encounter difficulties in 
the case of a multi-site investigation if some authorities classify it as 
audit and others as research. 
 
For example, a national audit of screening for diabetic retinopathy 
reported by Wilson et al. in the British Medical Journal (BMJ) involved 
collecting data from every health authority in England and 
Wales.26 While some health authorities saw the study as audit, others 
were unsure and passed it on to the relevant NHS local research 
ethics committee, with inconsistent results. Some ethics committees 
viewed the study as audit and outside their remit, some saw it as 
research, and others did not define it as either but felt that the use of 
patient questionnaires, access to NHS patients, or the use of an 
outside researcher warranted ethical approval. Some ethics committees 
were applying the (vague) definitions supported by the NHS. 
Arguably others were ignoring them completely and reviewing projects 
according to the risks posed to participants. Some of the 
problems experienced by Wilson et al. were resolved by the introduction 
of multi-centre research ethics committees in 1997. However 
the crux of the problem remains: audit is not within the remit of 
research ethics committees, which are subject to the same (lack of) 
guidance when it comes to differentiating between research and audit 
as investigators. Relying on them to define which borderline studies 
should be subjected to review potentially leads to inconsistency, delay 
and substandard protection of participants. 
 
Another problem is this: investigators who genuinely believe that 
they are conducting an audit may encounter resistance from journal 
editors if they decide to publish their findings and the editor views the 
study as research. Journal editors are subject to their own ethical 
code and will be reluctant to publish the results of what they perceive 
to be human research, without prior ethical review. A UK study 
published by the Lancet in 1998 demonstrates the problem well.27 The 
study was labelled an ‘audit of results from a clinical service’ and as 
such no ethical review was sought. It compared the prevalent method 
of detecting women at a high risk of carrying a foetus with trisomy 21 
(Down’s Syndrome) which involved a combination of the maternal 
age and a second-trimester maternal serum biochemistry with an 
emerging method, which combined maternal age with a nuchaltranslucency 
thickness ultrasound scan at the end of the first trimester. 
 
In 306 centres across the country, women attending routine 
antenatal care were offered the option of having their risk of trisomy 
21 assessed by measurement of the nuchal-translucency thickness at 
an ultrasound scan performed between 10 and 14 weeks gestation. 
They were given an information leaflet, told of the risks and given a 
request form to complete about the outcome of pregnancy. Many of 
these women would not have otherwise had a first trimester scan, 
which is performed transabdominally or, in cases of poor visualisation, 
transvaginally. The latter method is clearly invasive. Consent 
was obtained and an information sheet produced, but no independent 
ethics committee vetted the procedure. Pregnancy outcomes were 
obtained from maternity units, general practitioners or from the 
participating women; methods which raise data protection and confidentiality 
issues. The project also posed risks and benefits to the 
participants personally, directly affecting the care of the patients and 
their foetuses. The Lancet published the study but followed it with an 
editorial outlining the difficulties inherent in borderline studies.28 
The review system attempts to ensure adequate protection before 
the research begins; internal quality assurance or, in the case of 
clinical trials of investigational medicinal products, statutory regulation 
by the Medicines and Healthcare Products Regulatory Agency 
attempts to ensure that the recommendations are indeed being carried 
out; increasingly, journal editors are seen as a final barrier to 
unethical research. Where research is (intentionally or unintentionally) 
mislabelled as audit, the review system is bypassed altogether 
and the role of editors becomes especially important. Increasing 
numbers of audit studies are now published, but editors have no 
magic solution to the definition quandary. 
 
The Council of Science Editors,29 UK Committee on Publication 
Ethics (COPE),30 and the World Association of Medical Editors 
(WAME)31 all advise that the editor requires evidence of ethical 
review before publishing ‘research’.32 In borderline cases, journals 
might simply insist on prior ethical approval or a statement from the  
relevant ethics committee that review was not required. In this way 
they might abdicate responsibility. Yet a statement from an ethics 
committee that no review is required is not always the end of the 
matter. Given the current lack of certainty and resulting inconsistency 
editors arguably have a moral duty to consider the matter more 
deeply. In theory a journal editor might disagree with an ethics 
committee decision to classify a project as audit. Or a project may 
begin as audit but raise unexpected findings, which render a definition 
of research more appropriate. For articles submitted to the BMJ, 
its own ethics committee can be called upon to advise the editor in 
such cases. The BMJ’s submission guidance states that: 
 
Many people consider that studies referred to as audit do not need any consideration 
of ethics, whereas all research must be approved by a formally constituted research 
ethics committee or, in the USA, an institutional review board. But the distinction 
between audit and research is unclear, and the assumption that audit or analysing 
previously collected data is never unethical may not be justified. Furthermore, review 
by an ethics committee cannot necessarily guarantee that work is morally sound. For 
these reasons journals have a duty to consider the ethical aspects of both submitted 
and published work.33 
Members of COPE are advised to ensure that their journals have 
in place ‘a mechanism to ensure correct ethics committee or institutional 
review board approval’,34 which assumes some determination 
as to whether the study is correctly labelled as research or something 
else. The International Society of Medical Journal Editors35 insist 
that editors review the protocol to the extent that: 
If doubt exists whether the research was conducted in accordance with the Helsinki 
Declaration, the authors must explain the rationale for their approach and demonstrate 
that the institutional review body explicitly approved the doubtful aspects of 
the study.36 
But there are problems with editors subjecting studies to ethical 
scrutiny. The review is not independent and may not conform to 
national standards. It might conceivably undermine the decision of a 
NHS REC. 
 
An alternative is to refuse to publish borderline studies. The 
UBHT37 advises that the results of audit may be published without 
prior ethical approval, but journal editors may refuse to publish 
articles if there are ethical concerns and REC ethical approval has not 
been granted’. Given that audit is not currently within the remit of 
NHS RECs, whatever the ethical issues it might raise, this leaves 
authors in an unenviable position. It is also likely to allow valuable 
studies in the grey area between research and audit, to go unpublished. 
A third option is to demand that the study is given retrospective 
ethical approval. However this practice is barred in the UK. Retrospective 
review is occasionally utilised in Australia, but a clinical 
study published in the Medical Journal of Australia in 200138 led to 
debate about whether the practice was acceptable. Guidance followed 
in 200339 aimed at preventing the necessity for retrospective review. 
We will examine that guidance later. 
 
In the UK, the definitional problem is passed around from 
investigator, to ethics committee, to editor. No one has a definitive 
answer. One recent report in the BMJ lamented the continuing difficulties 
of getting quality improvement studies published: 
Journals treat quality improvement as research and wonder why there’s no ethics 
committee approval...And many, perhaps most, ethics committees are still unclear 
what to do with quality improvement proposals.40 
In consequence, despite efforts to create publishing avenues for 
clinical audit and other types of quality improvement (such as the 
Quality Improvement Report format in Quality and Safety in Heath 
Care), the results of clinical audit are under reported in the literature, 
hampering efforts to establish national standards of best practice. 
 
REFORM OF THE UK RESEARCH ETHICS SYSTEM 
In 2005, Lord Warner commissioned a review of the UK NHS 
research ethics committee system and subsequently recommended 
that: 
The remit of NHS RECs should not include surveys or other non-research activity if 
they present no material ethical issues for human participants. COREC should 
develop guidelines to aid researchers and committees in deciding what is appropriate 
or inappropriate for submission to RECs.41 
This implies two things. First, it implies counter-intuitively that 
survey-based studies are not research. This might be problematic in 
the rare cases where such surveys raise ethical issues. Second, it might 
imply that the remit of research ethics committees ought to include 
non-research activities if they involve significant ethical issues. The 
National Patient Safety Agency took on responsibility of COREC in 
2005. Together with COREC, it proposed an alternative interpretation 
of the CMO’s recommendation in 2006.42 The definition-based 
approach will be retained. Audit will remain outside the remit of 
RECs. The National Research Ethics Service was launched in April 
2007. A team of National Research Ethics Advisors (NREAs) will 
screen applications in order to identify studies which: 
 
1. fall outside the remit of NHS RECs; 
2. are patently of poor scientific quality or are poorly presented; 
3. apparently present no material ethical issues; 
4. are complex...[whereupon] the research ethics service will arrange 
for experts to provide...advice.43 
 
Low risk research will be considered by the NREAs, provided they 
contain ‘no material ethical issues’.44 Research of higher risk, and 
research containing material ethical issues, will go before a full research 
ethics committee. The service will operate on a continuous 
full-time basis so that straightforward studies can be approved 
without undue delay. This will also free up time so that ethics committees 
can concentrate on applications that require closer ethical 
scrutiny. There will therefore be advantages to investigators in terms 
of increased throughput and efficiency. At the same time the interests 
of potential research participants will also be protected by retaining 
independent ethical review of the majority of research in the NHS. A 
pilot screening process was launched in May 2007. 
 
Improved efficiency and greater proportionality promised by the 
reforms should be welcomed by investigators. Moreover, the incentive 
to circumvent the ethical review process by mislabelling audit as 
research should also be weaker under the proposed system, thereby 
strengthening the degree of protection afforded to potential research 
participants. However, uncertainty will still reign in the case of 
studies that fall on the borderline between research and audit. It 
remains the case that an NREA ought to reject such a proposal on 
the basis that it is outside the REC’s remit because it is judged to be 
an audit, regardless of the ethical issues inherent in the protocol. 
Guidance produced by the NPSA/COREC in 2006 does not shy away 
from the problem. It states: 
 
Although any of these [i.e. research, clinical audit and service evaluation] may raise 
ethical issues, under current guidance, research requires REC review, audit does not 
require REC review, service evaluation does not require REC review.45 
 
The proposed system will reduce delay and bureaucracy for 
researchers. It may even clarify the situation for ethics committees. It 
adds nothing of benefit to participants of audit projects that raise 
ethical issues and will result in confusion whenever a project does not 
fit neatly into the definition of research. 
 
ALTERNATIVE MODELS 
Rather than the definition of research taking centre stage in setting 
the limits of the remit of research ethics committees one could specify 
which activities require prior ethical review. This approach has been 
adopted in several European countries. In France, for example, prior 
ethical approval is only required for studies that involve medical 
intervention, medication, or physical risk.46 Elsewhere, in Denmark 
and The Netherlands for example, surveys and questionnaire-based 
studies are excluded from the requirement for prior ethical review. In 
the UK, the issue of whether or not to exclude surveys from the remit 
of RECs is still under consideration.47 
 
Currently in the UK, it is claimed that the research / audit distinction 
is an adequate proxy for risk. Likewise, the inclusion or 
exclusion of certain kinds of activities is justified on the basis that 
they generally involve greater or lesser risk. There is therefore a 
consensus that ethical review is warranted for studies which exceed or 
potentially exceed a certain threshold of risk. That threshold is usually 
referred to as ‘minimal risk’. Many definitions exist, but there is 
no universally accepted standard.48 There are many kinds of risk that 
are relevant in determining whether or not a project is ethical and 
opinions differ over which kinds of risk are the more important. 
Thus, the French ethical review system acknowledges risk of physical 
harm as the primary concern, whereas in the UK the risk of social 
and psychological harms is expressly recognised. Other less paternalistic 
approaches are possible. The moral philosopher John Harris, 
for example, emphasises the risk of undue influence.49 
 
A system which defines the requirement for independent ethical 
review by reference to a definition of research or of a certain activity 
will inevitably result in substandard review for those studies that fall 
on the borderlines of the definition or outside it altogether. As we 
have seen, this has potential to result in substandard protection for 
the participant, and also as a barrier to the publication of borderline 
studies. But what are the alternatives, and, equally important, are 
they proportionate? 
 
EXPEDITED REVIEW FOR RESEARCH AND AUDIT 
Another possibility would be to subject all biomedical research, 
including audit where that involves patients, participants, or their 
personal information, to independent ethical review. Historically in 
the UK, this would have lead to unacceptable delays in the approval 
of important studies. However, the screening system that is being 
introduced by the National Research Ethics Service may relieve such 
problems. It could be extended to apply to types of clinical audit. 
But would this constitute a proportionate use of time and 
resources? Arguably such outlay cannot be justified to protect participants 
in the few cases where research is mislabelled or audit raises 
ethical concerns. And there is another difficulty. Whilst there is an 
area of overlap between the two activities there are also instances 
when research and audit clearly differ. As currently constituted, 
research ethics committees may lack the required knowledge and 
expertise to evaluate some kinds of audit. The distinction between 
audit and research runs deep within the NHS. Auditors may feel 
uneasy about having their applications reviewed by a service that has 
little experience of reviewing audits. 
 
ABANDONING THE QUEST FOR A DEFINITION OF RESEARCH 
Australia’s National Statement on Ethical Conduct in Research 
Involving Humans50 implements a radical alternative. It does not attempt 
to define research,51 recognising that the meaning is dependant 
on context. Instead the emphasis is on defining the remit of Human 
Research Ethics Committees (HRECs).52 Consequently a broad view 
of research is taken and it is left to the investigator and the HREC to 
determine whether or not it is research and so subject to ethical 
review.53 It is risk to the participant that is the all-important factor in 
the Australian ethical review system. The Statement makes it explicit 
that, where participant involvement has potential for infringing basic 
ethical principles, review is warranted.54 
 
The Statement recognises the evolving research environment and 
the resulting need for flexibility in approach. On this basis, audit will 
not normally be included, but those rare cases of audit that have 
potential to infringe ethical principles can legitimately be incorporated 
within the remit of the HREC. This procedure, however, merely 
passes on the definition problem to the research ethics committees. 
Indeed the Statement recognises that: 
 
Researchers, regulators, funding bodies, institutions, organisations and HRECs will 
need to address these issues...and arrive at provisional descriptions of what constitutes 
research that merits ethical review. 55 
 
Accordingly the National Health and Medical Research Council 
published guidance in 2003.56 In Australia, the term ‘quality assurance’ 
(QA) is used. QA is wider than clinical audit. It can encompass 
types of health services research and a variety of quality improvement 
studies. The Australian guidance aims to protect participants, but 
also to facilitate QA, to help investigators determine when ethical 
review is necessary and to assist journal editors assessing articles for 
publication. The report notes that no authority has been able to 
adequately separate the definitions of QA and clinical research and 
consequently focuses on central features of any QA proposal that 
must be considered in deciding whether or not the proposal requires 
independent ethical review. 
 
Attempts to clearly separate quality assurance from research are 
difficult, and can be artificial and unhelpful. What really matters is 
that: 
 
(a) quality assurance is undertaken for a valid purpose and its 
outcomes are used to improve health care; and 
(b) those who undertake quality assurance adhere to relevant ethical 
principles and...legislation; and 
(c) where quality assurance proposals could infringe ethical principles 
that guide human research, independent ethical scrutiny of 
such proposals should be sought.57 
 
According to the guidance, QA can proceed without ethical review 
if either the participant gives informed consent or the results are fully 
and appropriately anonymised and participants are unlikely to suffer 
burden or harm.58 Section 5 breaks these issues down into a helpful 
list of questions. Only if all are answered in the negative can the 
investigator proceed without the advice of an independent ethics 
committee. Even when some answers are positive, however, the 
report advises that a detailed application or review by a full HREC 
will rarely prove necessary and sets down suggested means by which 
delegates of the HREC can swiftly deal with proposals involving 
minimal risk.59 
 
A system of expedited review operates in Australia. There are 
three levels of review in the Australian system: no independent review 
of minimal-risk quality assurance; expedited review of low-risk 
quality assurance and other research; full ethics committee review of 
higher risk research. The application process for expedited review is 
less onerous than an application for full review. Applications are 
screened and, if accepted for expedited review, will be evaluated by 
two HREC members; the investigator will be notified within two 
weeks whether or not the application has been approved. Alternatively, 
if an application for expedited review is not accepted, notice 
will be sent to the investigator that an application for full ethics 
committee review is required. 
 
The strengths of the Australian system are flexibility and sensitivity 
to the ethical significance of audit. There is however a danger 
that the system could fail to protect participants by relying on 
investigators to identify when ethics review may be required. Whilst 
the guidance is helpful, some investigators might try to avoid ethical 
scrutiny. However this risk can be overstated. Provided the system of 
expedited review ensures that minimal-risk studies are swiftly processed, 
investigators have little to gain by mislabelling their study and 
much to lose if they intend to publish the results. More problematic is 
the fact that opinions are likely to differ on a case by case basis as to 
what exactly constitutes more than minimal risk. This could lead to 
uncertainty and difficulties publishing audit that has not been subject 
to prior ethical review. In this respect, one troublesome definition 
(research) is replaced by another (minimal risk). For example, 
Maxwell and Kaye reported that their planned multi-site audit was 
severely delayed because the participating health authorities came to 
different conclusions over whether or not full ethics review was 
required.60 So, despite extensive guidelines, practical difficulties in 
allocating projects to the correct ethics review track are still evident. 
 
THE WAY FORWARD 
COREC defines the remit of ethics committees in paragraph 3.1 of its 
Governance Arrangements for NHS RECs (GAfREC). A second 
edition of GAfREC is expected in 2007. It is likely to develop an 
approach based on defining the activities which require prior ethical 
review. Audit will be excluded, possibly alongside NHS surveys.61 
The aim is to achieve proportionality: few studies which raise ethical 
 issues will bypass review. Some inevitably will. We have explored a 
number of alternative approaches. All clinical audit involving patients, 
participants or their personal information could be required to 
come under the ethical review umbrella. A system of expedited review 
would ensure that the vast majority of projects would be quickly 
turned around. Nevertheless, the cost in terms of time and resources 
would be prohibitive. Another option would be to follow the Australian 
model and abandon the quest for a definition of research. 
 
Instead, risk to the participant would be key. The investigator would 
bear the responsibility for deciding whether or not his study posed 
sufficient risk to the participant for ethical review to be warranted, 
and ethics committees would be given the authority to review any 
NHS project, research, audit, or service evaluation that raises ethical 
issues. There is much to recommend this system. But one problem 
with both alternatives is this: research ethics committees are not audit 
ethics committees. As we have seen there is a significant area of 
overlap between audit and research that can on occasion make the 
two activities difficult to distinguish, yet it is also true that there are 
significant differences between the two activities. Moreover, those 
differences are entrenched within the NHS. Arguably, even if the 
resources could be found to extend review to all studies raising ethical 
issues, the multiple differences between most research and most 
clinical audit would make the National Research Ethics Service an 
unsuitable reviewing body. Given the expenditure invested in the new 
research ethics system, the radical change required to implement a 
system based on the Australian model is unlikely to be embraced. 
We propose a fourth option. First, COREC would formally recognise 
that in borderline studies which contain ethical issues, RECs 
should err on the side of caution and submit the protocol to ethical 
review. This is probably what happens in many borderline cases in 
any event. At present, however, studies that are obviously audit but 
raise ethical issues, are not subject to review: there are incentives to 
mislabel research as audit, and investigators are unsure whether to 
publish studies raising ethical issues without prior ethical review. 
Additional measures are necessary. 
 
We therefore suggest that, second, Audit Committees in NHS 
organisations conducting clinical audit should be formalised. At 
present, no coherent system is in place to ensure that principles of 
good medical practice in audit are applied. Each healthcare organisation 
needs latitude in setting its own priorities for audit, and whilst 
guidance recommends a structured audit programme, including  
a committee structure and regular meetings, there is little guidance as 
to the constitution and remit of the committees and little to help them 
reach a decision as to the suitability of the particular study.62 
Arguably, greater formality is needed in the internal review of audit. 
Audit committees might even be required to include lay representatives 
who would be ideally placed to call attention to issues relating to 
participant protection. Audit committees would come under the 
inspection of the Healthcare Commission, enhancing confidence in 
their deliberations. Formal guidance would not only help ensure that 
audit is ethical, it might also raise the standard of audit. A number of 
articles have drawn attention to a quality gap, both in terms of ethics 
and scientific rigour between research and audit.63 The introduction 
of formal review of audit could help to close the quality gap, save 
resources from being wasted on ineffective audit and protect the 
rights and dignity of participants. But would the internal Audit 
Committee be suitably placed to review projects that do raise ethical 
issues? 
 
We think not and argue that, third, a clear pathway should be 
developed by which internal Audit Committees could pass those 
studies which raise ethical issues to an ethics committee. If the audit is 
conducted in a Trust which has a clinical ethics committee, then that 
committee may be suited to the task. Ideally, however, a National 
NHS Audit Ethics Committee would be set up. Low risk audit 
containing ethical issues could be dealt with by expedited review. 
Studies posing greater risk could be reviewed by the full committee. 
Just as we propose for RECs, the Audit Ethics Committee could be 
given the authority to review studies on the borderline between 
research and audit. This solution would protect research participants. 
It would also give confidence to investigators, ethics committees and 
journal editors. More audit would be published. And what is published 
would have been subjected to a consistent level of prior 
scientific and ethical review. 
 
There is a price to pay, and that price is delay. Recent reforms of 
the research ethical review process have aimed to ensure that internal 
NHS Research and Development (R&D) review occurs alongside 
independent ethical review in order to reduce duplication and delay. 
The method we propose involves the project going first to the internal 
Audit Committee and subsequently, if necessary, to the National 
Audit Ethics Committee. However the crucial difference is this: all 
NHS research must receive both R&D review and ethical review. In 
our case, only audit/borderline audit studies raising ethical issues 
would need to go before National Audit Ethics Committee. Cases are 
likely to be few: hence the need for only a single, national committee. 
The National Audit Ethics Committee would require detailed 
operational guidance. Currently the Principles of Best Practice in 
Clinical Audit recognises only that health service professionals 
‘should be aware of the ethical implications of audit’.64 The UBHT 
gives more substantive guidance65 which could be developed, alongside 
a consideration of the Australian guidance, into a suitable format 
for ethics committee use. 
 
The introduction of independent ethical review of audit has been 
suggested many times—sometimes by investigators themselves frustrated 
by the problematic distinction between audit and research.66 
Ethical review systems must strike an appropriate balance between 
the duty to protect participants and the duty to facilitate research and 
promote continued improvements in healthcare for the benefit of the 
wider public.67 There is a strong duty to facilitate clinical audit as the 
results are likely to have a direct impact on the quality of patient care. 
Thus, any changes to the regulation of clinical audit must be carefully 
considered so that they do not disproportionately impede studies of 
good quality. Such a system ought to be possible. Independent ethical 
review of audit would be reserved for those cases identified by 
internal audit committees. Even when ethical review is required, a 
triage system could reserve full review for studies involving more than 
minimal risk to participants. Review would be undertaken by people 
with the appropriate experience so that investigators could have 
confidence that reviewers understand the purpose and methodology 
of their study. The development of such a system is not necessarily 
antithetic to the duty to facilitate good quality audit. 
 
CONCLUSIONS 
Lack of clarity over the remit of research ethics committees and overreliance 
on confused definitions fail to serve the interests of investigators, 
research participants, and journal editors alike. Resources are 
wasted, progress is impeded, and participants are put at risk. A 
straightforward and transparent system of ethical review is needed, 
one that facilitates research and audit of good quality whilst ensuring 
that the rights and dignity of participants are respected. Current 
proposals for reform of the research ethics system should help to 
alleviate the concerns of researchers. However, further reforms are 
needed to ensure that participants are not put at risk or research 
impeded as a result of artificial distinctions between research and 
audit. Greater flexibility in the remit of research ethics committees 
combined with greater formality in the remit of Audit Committees 
within NHS organisations and the establishment of an independent 
National Audit Ethics Committee would achieve that goal. The cost, 
we argue, would be justified by the increased scientific and ethical 
quality of audit in the NHS. 
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